|
Apr 23
|
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement
|
|
Apr 23
|
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
|
|
Apr 22
|
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
|
|
Apr 21
|
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
|
|
Apr 21
|
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|
|
Apr 18
|
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
|
|
Apr 18
|
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
|
|
Apr 18
|
Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever
|
|
Apr 17
|
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
|
|
Apr 17
|
Sanofi licenses immune disease drugs from startup Earendil
|
|
Apr 16
|
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
|
|
Apr 15
|
Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
|
|
Apr 15
|
Tariff wars to hit popular US-made drugs in China, regulator data shows
|
|
Mar 14
|
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
|
|
Feb 23
|
Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
|
|
Feb 22
|
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 21
|
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
|
|
Feb 19
|
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
|